The first evidence on pharmacological ascorbate as a modulator of anti-tumor immunity in humans was reported in a clinical trial where NSCLC patients received pharmacological ascorbate with carboplatin and paclitaxel, and those with progression-free survival ≥ 6 months showed enhanced CD8+ activation by 4.2 fold compared to 1.6 fold in patients with progression-free survival < 6 months (86). This evidence concerns the gene CD8A and neoplasm.